CN1269720A - 增加骨容量的方法 - Google Patents

增加骨容量的方法 Download PDF

Info

Publication number: CN1269720A
Authority: CN; China
Prior art keywords: agonist; prostaglandin; application according; receptor; bone
Prior art date: 1997-09-09
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CN98808884A

Other languages

English (en)

Chinese (zh)

Inventor

J·R·哈特基

M·W·伦迪

M·A·德隆

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Procter and Gamble Co

Original Assignee

Procter and Gamble Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-09-09

Filing date

1998-09-04

Publication date

2000-10-11

1998-09-04 Application filed by Procter and Gamble Co filed Critical Procter and Gamble Co

2000-10-11 Publication of CN1269720A publication Critical patent/CN1269720A/zh

Status Pending legal-status Critical Current

Links

210000000988 bone and bone Anatomy 0.000 title claims abstract description 67
230000001965 increasing effect Effects 0.000 title claims abstract description 13
238000000034 method Methods 0.000 title abstract description 23
239000000556 agonist Substances 0.000 claims abstract description 38
102000003923 Protein Kinase C Human genes 0.000 claims abstract description 22
108090000315 Protein Kinase C Proteins 0.000 claims abstract description 22
239000011575 calcium Substances 0.000 claims abstract description 21
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 13
229910052791 calcium Inorganic materials 0.000 claims abstract description 13
239000003814 drug Substances 0.000 claims description 33
238000013459 approach Methods 0.000 claims description 26
150000003180 prostaglandins Chemical class 0.000 claims description 23
102000000471 Prostaglandin F receptors Human genes 0.000 claims description 21
108050008995 Prostaglandin F receptors Proteins 0.000 claims description 21
208000001132 Osteoporosis Diseases 0.000 claims description 14
210000000963 osteoblast Anatomy 0.000 claims description 14
230000001413 cellular effect Effects 0.000 claims description 12
102000015433 Prostaglandin Receptors Human genes 0.000 claims description 10
108010050183 Prostaglandin Receptors Proteins 0.000 claims description 10
WWSWYXNVCBLWNZ-QIZQQNKQSA-N fluprostenol Chemical compound C([C@H](O)\C=C\[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC(O)=O)OC1=CC=CC(C(F)(F)F)=C1 WWSWYXNVCBLWNZ-QIZQQNKQSA-N 0.000 claims description 10
229950009951 fluprostenol Drugs 0.000 claims description 10
206010022998 Irritability Diseases 0.000 claims description 7
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 5
229910052799 carbon Inorganic materials 0.000 claims description 5
125000000217 alkyl group Chemical group 0.000 claims description 4
230000008416 bone turnover Effects 0.000 claims description 4
DZUXGQBLFALXCR-CDIPTNKSSA-N prostaglandin F1alpha Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1CCCCCCC(O)=O DZUXGQBLFALXCR-CDIPTNKSSA-N 0.000 claims description 4
208000010191 Osteitis Deformans Diseases 0.000 claims description 3
208000027868 Paget disease Diseases 0.000 claims description 3
GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 claims description 3
229960001160 latanoprost Drugs 0.000 claims description 3
208000027202 mammary Paget disease Diseases 0.000 claims description 3
201000008482 osteoarthritis Diseases 0.000 claims description 3
208000001685 postmenopausal osteoporosis Diseases 0.000 claims description 3
FYBFDIIAPRHIQS-KKBLUXBBSA-N (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3R)-3-hydroxy-4-thiophen-3-yloxybut-1-enyl]cyclopentyl]hept-5-enoic acid Chemical compound C([C@H](O)\C=C\[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC(O)=O)OC=1C=CSC=1 FYBFDIIAPRHIQS-KKBLUXBBSA-N 0.000 claims description 2
208000010392 Bone Fractures Diseases 0.000 claims description 2
VJGGHXVGBSZVMZ-QIZQQNKQSA-N Cloprostenol Chemical compound C([C@H](O)\C=C\[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC(O)=O)OC1=CC=CC(Cl)=C1 VJGGHXVGBSZVMZ-QIZQQNKQSA-N 0.000 claims description 2
206010017076 Fracture Diseases 0.000 claims description 2
239000002253 acid Substances 0.000 claims description 2
229950004900 alfaprostol Drugs 0.000 claims description 2
125000001931 aliphatic group Chemical group 0.000 claims description 2
125000003118 aryl group Chemical group 0.000 claims description 2
125000002837 carbocyclic group Chemical group 0.000 claims description 2
229960004409 cloprostenol Drugs 0.000 claims description 2
125000000753 cycloalkyl group Chemical group 0.000 claims description 2
229950007806 delprostenate Drugs 0.000 claims description 2
229940032383 estrumate Drugs 0.000 claims description 2
229950004738 froxiprost Drugs 0.000 claims description 2
125000001072 heteroaryl group Chemical group 0.000 claims description 2
FNAMRDZHKYQEBA-YDQNNXAVSA-N methyl (2e,5z)-7-[(1r,2r,3r,5s)-2-[(e,3r)-4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hepta-2,5-dienoate Chemical compound COC(=O)\C=C\C\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(Cl)=C1 FNAMRDZHKYQEBA-YDQNNXAVSA-N 0.000 claims description 2
REFZGTXXBBUTMJ-YDQNNXAVSA-N methyl (2e,5z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(e,3r)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hepta-2,5-dienoate Chemical compound COC(=O)\C=C\C\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 REFZGTXXBBUTMJ-YDQNNXAVSA-N 0.000 claims description 2
OZDSQCVLNUIYLN-JNAAKWLTSA-N methyl (z)-7-[(1r,2s,3r,5s)-2-[(3s)-5-cyclohexyl-3-hydroxypent-1-ynyl]-3,5-dihydroxycyclopentyl]hept-5-enoate Chemical compound COC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1C#C[C@@H](O)CCC1CCCCC1 OZDSQCVLNUIYLN-JNAAKWLTSA-N 0.000 claims description 2
208000005368 osteomalacia Diseases 0.000 claims description 2
229910052760 oxygen Inorganic materials 0.000 claims description 2
201000007094 prostatitis Diseases 0.000 claims description 2
IFEJLMHZNQJGQU-KXXGZHCCSA-M sodium;(z)-7-[(1r,2r,3r,5s)-2-[(e,3r)-4-(3-chlorophenoxy)-3-hydroxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate Chemical compound [Na+].C([C@H](O)\C=C\[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC([O-])=O)OC1=CC=CC(Cl)=C1 IFEJLMHZNQJGQU-KXXGZHCCSA-M 0.000 claims description 2
MUVLUMTZYKYXRV-KXXGZHCCSA-M sodium;(z)-7-[(1r,2r,3r,5s)-3,5-dihydroxy-2-[(e,3r)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoate Chemical compound [Na+].C([C@H](O)\C=C\[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC([O-])=O)OC1=CC=CC(C(F)(F)F)=C1 MUVLUMTZYKYXRV-KXXGZHCCSA-M 0.000 claims description 2
229910052717 sulfur Inorganic materials 0.000 claims description 2
125000003831 tetrazolyl group Chemical group 0.000 claims description 2
229950002099 tiaprost Drugs 0.000 claims description 2
230000004913 activation Effects 0.000 abstract description 11
208000020084 Bone disease Diseases 0.000 abstract description 2
230000003834 intracellular effect Effects 0.000 abstract description 2
230000037361 pathway Effects 0.000 abstract description 2
230000003213 activating effect Effects 0.000 abstract 1
230000001582 osteoblastic effect Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 description 13
230000000694 effects Effects 0.000 description 13
230000003203 everyday effect Effects 0.000 description 11
102000005962 receptors Human genes 0.000 description 10
108020003175 receptors Proteins 0.000 description 10
239000000203 mixture Substances 0.000 description 9
238000012360 testing method Methods 0.000 description 9
210000004027 cell Anatomy 0.000 description 8
239000003795 chemical substances by application Substances 0.000 description 8
210000001519 tissue Anatomy 0.000 description 7
239000002552 dosage form Substances 0.000 description 6
239000003937 drug carrier Substances 0.000 description 6
230000037396 body weight Effects 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
108010048734 sclerotin Proteins 0.000 description 5
238000007920 subcutaneous administration Methods 0.000 description 5
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
238000005259 measurement Methods 0.000 description 4
239000008194 pharmaceutical composition Substances 0.000 description 4
230000003442 weekly effect Effects 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
239000000463 material Substances 0.000 description 3
230000005486 microgravity Effects 0.000 description 3
210000000582 semen Anatomy 0.000 description 3
230000016160 smooth muscle contraction Effects 0.000 description 3
239000000243 solution Substances 0.000 description 3
206010065687 Bone loss Diseases 0.000 description 2
MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
230000002421 anti-septic effect Effects 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
238000002591 computed tomography Methods 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
238000001647 drug administration Methods 0.000 description 2
238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
230000001976 improved effect Effects 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
239000007788 liquid Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
238000002595 magnetic resonance imaging Methods 0.000 description 2
238000002156 mixing Methods 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
239000000049 pigment Substances 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
229920000747 poly(lactic acid) Polymers 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
239000004626 polylactic acid Substances 0.000 description 2
238000011084 recovery Methods 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
238000010254 subcutaneous injection Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000000758 substrate Substances 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
DZUXGQBLFALXCR-UHFFFAOYSA-N (+)-(9alpha,11alpha,13E,15S)-9,11,15-trihydroxyprost-13-en-1-oic acid Natural products CCCCCC(O)C=CC1C(O)CC(O)C1CCCCCCC(O)=O DZUXGQBLFALXCR-UHFFFAOYSA-N 0.000 description 1
PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
208000006386 Bone Resorption Diseases 0.000 description 1
206010006482 Bronchospasm Diseases 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
108091006068 Gq proteins Proteins 0.000 description 1
102000052606 Gq-G11 GTP-Binding Protein alpha Subunits Human genes 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
241000282341 Mustela putorius furo Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
241001597008 Nomeidae Species 0.000 description 1
102000016979 Other receptors Human genes 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
206010039984 Senile osteoporosis Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
239000004141 Sodium laurylsulphate Substances 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
206010047139 Vasoconstriction Diseases 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000032683 aging Effects 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000002968 anti-fracture Effects 0.000 description 1
229940006138 antiglaucoma drug and miotics prostaglandin analogues Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
-1 antiseptic Substances 0.000 description 1
229940114079 arachidonic acid Drugs 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
238000010170 biological method Methods 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
230000037058 blood plasma level Effects 0.000 description 1
210000002805 bone matrix Anatomy 0.000 description 1
230000004097 bone metabolism Effects 0.000 description 1
230000024279 bone resorption Effects 0.000 description 1
238000000339 bright-field microscopy Methods 0.000 description 1
230000007885 bronchoconstriction Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
238000010523 cascade reaction Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
MVQBFZXBLLMXGS-UHFFFAOYSA-N chembl331220 Chemical compound C1=CC=C2C(N=NC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C=C(S(O)(=O)=O)C2=C1 MVQBFZXBLLMXGS-UHFFFAOYSA-N 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
239000000512 collagen gel Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000006184 cosolvent Substances 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000000151 deposition Methods 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
235000013681 dietary sucrose Nutrition 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
XQRLCLUYWUNEEH-UHFFFAOYSA-L diphosphonate(2-) Chemical compound [O-]P(=O)OP([O-])=O XQRLCLUYWUNEEH-UHFFFAOYSA-L 0.000 description 1
238000007907 direct compression Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
230000000857 drug effect Effects 0.000 description 1
150000002066 eicosanoids Chemical class 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
210000000704 endosteal cell Anatomy 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000000799 fluorescence microscopy Methods 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
210000002149 gonad Anatomy 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000002960 lipid emulsion Substances 0.000 description 1
239000002502 liposome Substances 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000003550 marker Substances 0.000 description 1
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
238000013425 morphometry Methods 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000002674 ointment Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
210000004409 osteocyte Anatomy 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
239000006072 paste Substances 0.000 description 1
208000028169 periodontal disease Diseases 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
238000012207 quantitative assay Methods 0.000 description 1
238000011552 rat model Methods 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
238000012552 review Methods 0.000 description 1
230000000630 rising effect Effects 0.000 description 1
238000012216 screening Methods 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
229960004793 sucrose Drugs 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000000454 talc Substances 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
102000027257 transmembrane receptors Human genes 0.000 description 1
108091008578 transmembrane receptors Proteins 0.000 description 1
230000025033 vasoconstriction Effects 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

Health & Medical Sciences (AREA)
Physical Education & Sports Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

CN98808884A 1997-09-09 1998-09-04 增加骨容量的方法 Pending CN1269720A (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US5821897P	1997-09-09	1997-09-09
US60/058,218		1997-09-09

Publications (1)

Publication Number	Publication Date
CN1269720A true CN1269720A (zh)	2000-10-11

Family

ID=22015432

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CN98808884A Pending CN1269720A (zh)	1997-09-09	1998-09-04	增加骨容量的方法

Country Status (17)

Country	Link
EP (1)	EP1035853A1 (es)
JP (1)	JP2001515863A (es)
CN (1)	CN1269720A (es)
AR (1)	AR013478A1 (es)
AU (1)	AU9130298A (es)
BR (1)	BR9811775A (es)
CA (1)	CA2303799A1 (es)
CO (1)	CO5070621A1 (es)
HU (1)	HUP0003584A3 (es)
ID (1)	ID24759A (es)
IL (1)	IL134759A0 (es)
NO (1)	NO20001172L (es)
PE (1)	PE118899A1 (es)
PL (1)	PL339297A1 (es)
SK (1)	SK3402000A3 (es)
WO (1)	WO1999012550A1 (es)
ZA (1)	ZA988229B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUP0200258A2 (hu)	1999-03-05	2002-05-29	The Procter & Gamble Co.	C16-telítetlen FP-szelektív prosztaglandin analógok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
US20020013294A1 (en)	2000-03-31	2002-01-31	Delong Mitchell Anthony	Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en)	2000-03-31	2002-11-21	Delong Michell Anthony	Compositions and methods for treating hair loss using non-naturally occurring prostaglandins

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU3607293A (en) *	1992-02-05	1993-09-03	Merck & Co., Inc.	Implant therapy for bone growth stimulation
HN1996000101A (es) *	1996-02-28	1997-06-26	Inc Pfizer	Terapia combinada para la osteoporosis

1998
- 1998-09-04 BR BR9811775-0A patent/BR9811775A/pt not_active Application Discontinuation
- 1998-09-04 SK SK340-2000A patent/SK3402000A3/sk unknown
- 1998-09-04 IL IL13475998A patent/IL134759A0/xx unknown
- 1998-09-04 WO PCT/US1998/018337 patent/WO1999012550A1/en not_active Application Discontinuation
- 1998-09-04 CN CN98808884A patent/CN1269720A/zh active Pending
- 1998-09-04 AU AU91302/98A patent/AU9130298A/en not_active Abandoned
- 1998-09-04 JP JP2000510447A patent/JP2001515863A/ja not_active Withdrawn
- 1998-09-04 PL PL98339297A patent/PL339297A1/xx unknown
- 1998-09-04 CA CA002303799A patent/CA2303799A1/en not_active Abandoned
- 1998-09-04 HU HU0003584A patent/HUP0003584A3/hu unknown
- 1998-09-04 EP EP98943532A patent/EP1035853A1/en not_active Withdrawn
- 1998-09-04 ID IDW20000638A patent/ID24759A/id unknown
- 1998-09-08 AR ARP980104480A patent/AR013478A1/es not_active Application Discontinuation
- 1998-09-09 PE PE1998000855A patent/PE118899A1/es not_active Application Discontinuation
- 1998-09-09 CO CO98051809A patent/CO5070621A1/es unknown
- 1998-09-09 ZA ZA988229A patent/ZA988229B/xx unknown
2000
- 2000-03-07 NO NO20001172A patent/NO20001172L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
WO1999012550A1 (en)	1999-03-18
SK3402000A3 (en)	2000-12-11
PE118899A1 (es)	2000-02-03
ID24759A (id)	2000-08-03
AR013478A1 (es)	2000-12-27
JP2001515863A (ja)	2001-09-25
BR9811775A (pt)	2000-08-29
PL339297A1 (en)	2000-12-04
EP1035853A1 (en)	2000-09-20
CA2303799A1 (en)	1999-03-18
HUP0003584A2 (hu)	2001-02-28
NO20001172L (no)	2000-05-08
NO20001172D0 (no)	2000-03-07
ZA988229B (en)	1999-03-09
AU9130298A (en)	1999-03-29
CO5070621A1 (es)	2001-08-28
HUP0003584A3 (en)	2002-12-28
IL134759A0 (en)	2001-04-30

Legal Events

Date	Code	Title
2000-10-11	C06	Publication
2000-10-11	PB01	Publication
2000-10-18	C10	Entry into substantive examination
2000-10-18	SE01	Entry into force of request for substantive examination
2001-12-26	C02	Deemed withdrawal of patent application after publication (patent law 2001)
2001-12-26	WD01	Invention patent application deemed withdrawn after publication

Publication	Publication Date	Title
CN1269721A (zh)	2000-10-11	用非天然存在的fp选择性激动剂增加骨容量的方法
CN1102388C (zh)	2003-03-05	用羟基咔唑化合物抑制平滑肌的移行与增生
EP2020999B1 (en)	2011-08-31	Compositions comprising alpha-ketoglutarate and their use for modulating muscle performance
CN1269720A (zh)	2000-10-11	增加骨容量的方法
US20030158247A1 (en)	2003-08-21	Pharmaceutical composition comprising a sodium hydrogen exchange inhibitor and an angiotensin converting enzyme inhibitor
CN1233150A (zh)	1999-10-27	抑制fas表达的方法
US7238718B2 (en)	2007-07-03	Method for treating myolytic disease and method for screening antimyolytic agent
CN1293877C (zh)	2007-01-10	神经营养性藤霉素类似物
EP1158969A2 (en)	2001-12-05	Use of a non-naturally-occurring ep1 selective agonist for increasing bone volume
Welch et al.	1996	Intraosseous infusion of prostaglandin E2 prevents disuse‐induced bone loss in the tibia
WO2000051616A1 (en)	2000-09-08	Method of increasing bone volume using non-naturally-occurring selective fp agonist and dito ep1 agonist prostaglandin derivatives
JPH1135470A (ja)	1999-02-09	ビタミンｄ３誘導体を含有する副甲状腺ホルモン産生促進剤
CN1346278A (zh)	2002-04-24	麻醉的调节
JP5042419B2 (ja)	2012-10-03	骨形成促進剤および骨形成促進組成物
JPH0216288B2 (es)	1990-04-16
CN1708308A (zh)	2005-12-14	福辛普利降低透析患者心血管事件的用途
MXPA00002395A (es)	2001-12-04	Metodo para incrementar el volumen oseo
MXPA00002394A (es)	2001-12-13	Metodo para incrementar el volumen oseo usando agonistas selectivos de prostanoide f no naturales
CZ2000808A3 (cs)	2000-06-14	Použití selektivního FP agonisty, který se přirozeně nevyskytuje
JP2002538122A (ja)	2002-11-12	天然に存在しないｆｐ選択的アゴニストおよび骨吸収抑制化合物を用いる骨体積の増加方法
CN1433302A (zh)	2003-07-30	氢化可的松拮抗剂在治疗心力衰竭中的应用